Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-09-15 16:44:04 ET · period of report 2026-09-15 · accession 0001193125-26-392025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-15 16:44 | 2026-09-15 | ARTV | Aslan Fred | CEO, Dir | A - Grant | $0.00 | +110.0K | 1.60M | +7% | $0 |
| D | 2026-09-15 16:44 | 2026-09-15 | ARTV | Aslan Fred | CEO, Dir | A - Grant | $0.00 | +315.0K | 315.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | A | A | 110,000 | $0.00 | 1,604,765 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2026-09-15 | A | A | 315,000 | $0.00 | 315,000 | D | $8.91 · — to 2036-09-14 | 315,000 Common Stock | (F2) Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. |